References
- Gerrard J M, White JG. Prostaglandins and thromboxanes: “middlemen” modulator platelet function in hae-mostasis and thrombosis. Prog Hemost Thromb 1978; xx: 87–125
- Kallenberg C G, Vallenga E, Wouda A A, et al. Platelet activation, fibrinolytic activity and circulating immune complexes in Raynaud's phenomenon. J Rheumatol 1982; 9(6)878–84
- Hutton R A, Mikhailidis D P, Bernstein R M, et al. Assessment of platelet function in patients with Raynaud's syndrome. J Clin Pathol 1984; 37: 182–7
- Biondi M L, Marasini B, Bianehi E, et al. Plasma free and intra platelet serotonin in patient with Raynaud's phenomenon. Int J Cardiol 1988; 19(3)335–9
- Wilkinson D, Vowden P, Gilks L, et al. Plasma eicosanoids, platelet function and cold sensitivity. Br J Surg 1989; 76: 401–5
- Kahaleh M B, Osborn I, LcRoy EC. Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Intern Med 1982; 96: 610–3
- Saniabadi A R, Lowe G DO, Forbes C D, et al. Platelet aggregation studies in whole human blood. Thromb Res 1983; 30: 625–32
- Lau C S, McLaren M, Walker M, Belch J JF. Baseline plasma fibrinolysis and its correlation with clinical manifestations in patients with Raynaud's phenomenon. Ann Rheum Dis, in press
- Clauss A. Gernnungs physiologische Schnell method zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237–51
- Masi A T, Rodhan G P, Medeger T A, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581–90
- Zahavi J, Hamilton W AP, O'Reilly M JG, et al. Plasma exchange and platelet function in Raynaud's phenomenon. Thromb Res 1980; 19: 85–93
- Reilly I AG, Roy L, Fitzgerald GA. Biosynthesis of throm-boxane in patients with systemic sclerosis and Raynaud's phenomenon. Br Med J 1986; 292: 1037–9
- Belch J JF, O'Dowd A, Forbes C D, et al. Platelet sensitivity to a prostacyclin analogue in systemic sclerosis. Br J Rheumatol 1985c; 24: 346–50
- Biondi M L, Marasini B. Abnormal platelet aggregation in patients with Raynaud's phenomenon. J Clin Pathol 1989; 42: 716–8
- Wilkinson D, Vowden P, Gilks L, et al. Plasma eicosa-noids, platelet function and cold sensitivity. Br J Surg 1989; 76: 401–5
- Price J E, Klimiuk P S, Jayson M, IV. In vitro platelet agree ability studies: lack of evidence for platelet hyper-aggregability in systemic sclerosis. Ann Rheum Dis 1991; 5O: 567–71
- Blackwell G J, Flower R J, Russell-Smith N, et al. Prostacyclin is produced in whole blood. Br J Pharmacol (proceedings) 1978; 64(3)436P
- Belch J JF. The role of the white blood cell in arterial disease. Blood Coag Fibrinol 1990; 1: 183–92
- Gaarder A, Jonsen J, Laland J, et al. Adenosine diphosphate in red cells as a factor in adhesiveness of human blood platelets. Nature 1961; 192: 531–2
- Born G VR, Wehmeier A. Inhibition of platelet thrombus formation of Chlorpromazine acting to diminish haemolysis. Nature 1979; 5735: 212–3
- Karpatkin S, Charmartz A. Heterogeneity of human platelets. J Clin Invest 1969; 48: 1073–87
- Lau C S, McLaren M, Belch J JF. Fdctor VIII von Wil-lebrand Factor antigen levels correlate with symptom severity in patients with Raynaud's phenomenon. Br J Rheumatol 1991; 30: 433–6
- Bloom A L, Giddings J C, Wilks CJ. Factor VIII on the vascular intima: a possible importance in haemostasis and thrombosis. Nature (New Biol) 1973; 241: 217–9
- Saniabadi A R, Lowe G DO, Barbenel J C, et al. Further studies on the role of red blood cells in spontaneous platelet aggregation. Thromb Res 1985; 38(3)225–32
- Dowd P M, Kovas I B, Bland C JH, et al. Effects of prostaglandin I, and E, on red cell deformability in patients with Raynaud's phenomenon and systemic sclerosis. Br Med J 1981; 183: 350
- Lau C S, Bridges A B, Muir A, et al. Further evidence of increased polymorphonuclear cell activity in patients with Raynaud's phenomenon. Br J Rheumatol 1992; 31: 375–80
- Kallenberg C G, Wouda A A, Hoet MH. Systemic involvement and immunological findings in patients presenting with Raynaud's phenomenon. Am J Med 1980; 69: 675–80